B Cell Acute Lymphoblastic Leukemia: Signs, Causes & Treatment

• Early Pre-B Cell ALL: This type occurs in early B-cell precursors and represents one of the earliest stages of B-cell development affected by the disease.
• Pre-B Cell ALL: In this subtype, leukemic cells resemble pre-B cells and express CD19, CD10, and TdT markers.
• B-cell ALL with t(9;22)(q34.1;q11.2); BCR-ABL1: This type is characterised by the presence of the Philadelphia chromosome, resulting from a translocation between chromosomes 9 and 22.
• Ph-like B-cell ALL: Commonly found in adolescents and adults, this subtype resembles Philadelphia chromosome-positive ALL but lacks the BCR-ABL1 fusion gene.
• Hyperdiploid ALL: This subtype has extra chromosomes, typically multiples of 5, and is generally associated with a more favourable prognosis.
• E2A-PBX1 ALL: This type is associated with a fusion of the E2A and PBX1 genes and has distinct clinical characteristics.

• Fatigue and weakness are common symptoms of B-cell acute lymphoblastic leukemia due to the impact on healthy blood cells.
• Unexplained weight loss can occur as a result of various metabolic changes caused by the disease.
• Frequent infections or illnesses may be experienced due to a compromised immune system.
• Bone pain and tenderness can be a presenting symptom as the cancer affects the bone marrow.
• Easy bruising or bleeding tendencies are often seen due to low platelet counts.
• Pale skin, fever, loss of appetite, night sweats, and abdominal discomfort may also be present.

• Genetic predisposition, such as chromosomal abnormalities, can contribute to the development of B-cell acute lymphoblastic leukemia.
• Exposure to radiation, including high doses of ionising radiation, is a known risk factor for this disease.
• Certain inherited genetic syndromes, like Down syndrome, are associated with an increased risk of developing B-cell acute lymphoblastic leukemia.
• Previous treatment with certain chemotherapy drugs, particularly alkylating agents and topoisomerase II inhibitors, can increase the risk of developing this leukemia.
• A family history of leukemia may also contribute to an individual's overall risk.

• Persistent fatigue, paleness, or shortness of breath that does not improve with rest, possibly indicating anemia from abnormal blood cell production.
• Unexplained bruising, bleeding gums, or tiny red spots (petechiae) on the skin suggesting low platelet levels.
• Swollen lymph nodes, recurring fevers, or frequent infections lasting more than a week without a clear cause.

• You experience sudden, severe headache, vision changes, or confusion, which may indicate leukemia spreading to the central nervous system.
• You have uncontrolled bleeding, extremely high fever with chills, or signs of severe infection such as rapid heart rate and low blood pressure.
• Severe difficulty breathing or chest pain develops suddenly, requiring emergency evaluation without delay.

• A physical examination and medical history review help assess symptoms and identify potential risk factors.
• Blood tests, including a complete blood count and peripheral blood smear, may reveal abnormal cell counts and morphology.
• Bone marrow aspiration and biopsy are performed to confirm the presence of abnormal B lymphoblasts in the bone marrow.
• Flow cytometry, cytogenetic analysis, and molecular testing help subtype the leukemia and guide treatment decisions.
• Imaging studies such as X-rays, CT scans, or MRIs may be done to evaluate the extent of the disease and detect any complications.

• Chemotherapy is often the first line of treatment and is administered in phases to maximise its effectiveness in killing cancer cells.
• Targeted therapy specifically targets cancer cells while minimising damage to surrounding healthy cells.
• Radiation therapy may be used to treat specific areas affected by leukemia, particularly when the disease spreads to the central nervous system.
• Stem cell transplantation, also known as a bone marrow transplant, can be considered in certain cases to help restore healthy blood cell production.
• Regular monitoring and supportive care are also essential components of managing B-cell acute lymphoblastic leukemia throughout the course of treatment.

• Genetic predisposition, including inherited genetic syndromes like Down syndrome, increases the risk of B-cell acute lymphoblastic leukemia.
• Exposure to high levels of radiation, such as prior cancer treatments involving radiation therapy, is a recognised risk factor.
• Certain genetic mutations, like alterations in the IKZF1 gene, are associated with an increased risk of developing this condition.
• Environmental factors, such as exposure to chemicals like benzene or other toxins, may contribute to its development.
• A weakened immune system, particularly in individuals who have undergone organ transplantation, may also play a role.
• Being male is a risk factor for B-cell acute lymphoblastic leukemia.

What Is the Recovery Process for B-Cell Acute Lymphoblastic Leukemia?

Recovery from B-cell acute lymphoblastic leukemia varies significantly from person to person depending on factors such as age, overall health, disease subtype, and how well the cancer responds to treatment. Understanding what the recovery journey involves can help patients and families prepare and stay engaged throughout the process.